米国のオピオイド鎮痛薬市場：製品タイプ別、投与経路別、用途別、流通チャネル別、地域別、機会、予測、2018年～2032年

米国のオピオイド鎮痛薬の市場規模は、予測期間の2025年～2032年に3.64％のCAGRで拡大し、2024年の121億6,000万米ドルから2032年には161億5,000万米ドルに成長すると予測されています。高齢化人口の増加、慢性疾患の有病率の上昇、術後疼痛管理を補助する製品への要求の高まりは、米国におけるオピオイド鎮痛薬市場の成長を促進する主な要因の一部です。人口問題研究所の推計によると、65歳以上のアメリカ人の数は2022年から2050年にかけて47%増加すると予想されています。

市場の成長は、大手市場参入企業の強い存在感、研究開発活動への継続的な投資、米国における医療支出の増加によっても支えられています。研究機関やヘルスケア機関は、より安全なオピオイド代替薬の開発や、有害事象を監視するための市販後調査に注力しています。さらに、米国では外科手術の件数が増加し続けており、急性期医療におけるオピオイドの需要をさらに押し上げています。

当レポートでは、米国のオピオイド鎮痛薬市場について調査し、市場の概要とともに、製品タイプ別、投与経路別、用途別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 米国のオピオイド鎮痛薬市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
• 2024年の市場マップ分析
  • 製品タイプ別
  • 投与経路別
  • 用途別
  • 流通チャネル別
  • 地域別

第5章 バリューチェーン分析

第6章 ポーターのファイブフォース分析

第7章 PESTLE分析

第8章 価格分析

第9章 市場力学

• 市場の促進要因
• 市場の課題

第10章 市場動向と発展

第11章 規制枠組みとイノベーション

第12章 臨床試験の概要

第13章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Endo Pharmaceuticals Inc.
  • Sanofi S.A.
  • Daiichi Sankyo, Inc.
  • Hikma Pharmaceuticals USA Inc.
  • Purdue Pharma L.P.
  • Mundipharma Pty Limited
  • Protega Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals plc

第14章 戦略的提言

第15章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Opioid Analgesics Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Opioid Analgesics Market Share (%), By Product Type, 2018-2032F
• Figure 3. United States Opioid Analgesics Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. United States Opioid Analgesics Market Share (%), By Application, 2018-2032F
• Figure 5. United States Opioid Analgesics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 6. United States Opioid Analgesics Market Share (%), By Region, 2018-2032F
• Figure 7. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

United States opioid analgesics market is projected to witness a CAGR of 3.64% during the forecast period 2025-2032, growing from USD 12.16 billion in 2024 to USD 16.15 billion in 2032. The growth of the aging population, rising prevalence of chronic diseases, and increasing requirement for products that aid in management of post-operative pain are some of the major factors driving the growth of the opioid analgesics market in the United States. According to the estimates of the Population Reference Bureau, the number of Americans that are 65 and older is expected to witness a 47% increase from 2022 to 2050.

The market's growth is also supported by the strong presence of major market players, continuous investments in research and developments activities, and increasing healthcare expenditure in the United States. Research institutions and healthcare organizations are focusing on developing safer opioid alternatives and in post-marketing surveillance to monitor adverse events. Additionally, the United States continues to witness increase in the number of surgical procedures, further driving the demand for opioids in acute care setting.

Expansion of the Aging Population Boosts Market Demand

The rapid growth of the aging population is one of the major drivers of the market as the elderly are more prone to age-related chronic conditions such as neuropathic pain and arthritis, among others. In such conditions, the patients often rely on effective pain management solutions, resulting in a higher requirement for opioid analgesics. Additionally, the older population is also more likely to undergo surgical procedures, frequently necessitating postoperative pain relief. They are also susceptible to injuries and degenerative diseases, further amplifying the requirement for potent pain relief solutions. As per the estimates of the Christopher & Dana Reeve Foundation, approximately 18,000 new spinal cord injuries are reported every year in the United States.

Meanwhile, pharmaceutical companies and healthcare professionals are increasingly focusing on personalized medicines and customized pain management strategies in order to align with the unique pain management requirements of the older population.

Increasing Focus on Abuse-Deterrent Formulations (ADFs) Supports Market Expansion

The focus on developing ADFs has significantly increased over the past few years in order to address the ongoing opioid crisis by maintaining the pain relief benefits of opioids for genuine patients while reducing the potential for abuse. The Food and Drug Administration (FDA) is actively encouraging the development and introduction of ADFs, promoting collaborations among specialty pharmaceutical companies. For instance, in March 2025, Protega Pharmaceuticals Inc. and Wellgistics Health partnered with each other to enhance pharmacist education and improve patient access to ROXYBOND, the first and only FDA-approved abuse-deterrent immediate-release opioid in the United States. Such initiatives are directed towards addressing the more complicated issue of pain management and opioid prescribing and seek to promote safer opioid utilization and reduce the risks associated with opioid use.

Mergers and Acquisitions Drive Market Growth

Such strategic initiatives are allowing leading pharmaceutical companies to improve their research and development capabilities, expand their product portfolios, and strengthen their market presence. Additionally, pharmaceutical giants are also focusing on mergers and acquisitions due to the major financial challenges faced by various companies during the opioid crisis and opioid-related litigation. For instance, in March 2025, Mallinckrodt Pharmaceuticals plc and Endo Pharmaceuticals Inc. announced a USD 6.7 billion merger that is expected to close in the second half of 2025. Both companies have faced financial challenges due to opioid-related litigation and are seeking to create a more resilient pharmaceutical entity with enhanced resources for innovation and growth, with this merger. This collaboration is also expected to enhance their financial stability and strengthen their position in the market.

Retail Pharmacies Hold Major Market Share

Due to their accessibility, extensive reach, and role in dispensing prescription medications, retail pharmacies hold a major share in the United States opioid analgesics market. These pharmacies serve as the primary distribution channel for opioid analgesics for patients suffering from chronic pain, among other medical conditions. Additionally, patients also prefer retail pharmacies due to their convenient nature. Retail pharmacies cater to patients across all regions, including those living in rural and underserved areas. Additionally, retail pharmacies play a vital role in ensuring compliance for opioid use with regulatory guidelines. They are able to monitor prescriptions and dispense the proper dosages while providing counseling to patients regarding the use of opioids. Thus, bolstering the segment's expansion.

Future Market Scenario (2025 - 2032F)

The United States opioid analgesics market is expected to witness significant growth in the coming years, driven by rising demand for the treatments for acute and chronic pain, advancements in formulations, and increasing awareness about responsible opioid use. While the opioid epidemic is a major challenge, collaborative industry and regulatory efforts are supporting the market's revival. Increasing focus on dual-action painkillers, utilization of biosensors for personalized pain management therapy, and artificial intelligence for prescription management are expected to provide lucrative growth opportunities for the market.

Key Players Landscape and Outlook

The new tariffs in the United States are significantly impacting the market, with leading players focusing on shifting their manufacturing operations to the United States. In March 2025, Pfizer Inc. announced plans to move its manufacturing operations to the United States, leveraging its existing 13 United States production plants, including production facilities for antibodies and sterile injectables.

The market players are also focusing on introducing new products in order to maintain their position in the industry. For instance, In February 2024, Hikma Pharmaceuticals USA Inc. launched Fentanyl Citrate Injections, USP, in 25mcg/0.5mL and 50mcg/mL doses. The product has been launched in the United States and is indicated for short-duration analgesic action, premedication, induction, and maintenance, as well as in the immediate postoperative period as per the patient requirement.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States Opioid Analgesics Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Codeine
    • 4.2.1.2. Morphine
    • 4.2.1.3. Oxycodone
    • 4.2.1.4. Hydrocodone
    • 4.2.1.5. Methadone
    • 4.2.1.6. Meperidine
    • 4.2.1.7. Fentanyl
    • 4.2.1.8. Hydromorphone
    • 4.2.1.9. Oxymorphone
    • 4.2.1.10. Dextromethorphan
    • 4.2.1.11. Tramadol
    • 4.2.1.12. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Oral
    • 4.2.2.2. Injectable
    • 4.2.2.3. Others
  • 4.2.3. By Application
    • 4.2.3.1. Chronic Pain
    • 4.2.3.2. Acute Pain
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. Northeast
    • 4.2.5.2. Southwest
    • 4.2.5.3. West
    • 4.2.5.4. Southeast
    • 4.2.5.5. Midwest
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Product Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Application
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Value Chain Analysis

6. Porter's Five Forces Analysis

7. PESTLE Analysis

8. Pricing Analysis

9. Market Dynamics

• 9.1. Market Drivers
• 9.2. Market Challenges

10. Market Trends and Developments

11. Regulatory Framework and Innovation

12. Clinical Trial Overview

13. Competitive Landscape

• 13.1. Competition Matrix of Top 5 Market Leaders
• 13.2. SWOT Analysis for Top 5 Players
• 13.3. Key Players Landscape for Top 10 Market Players
  • 13.3.1. Pfizer Inc.
    • 13.3.1.1. Company Details
    • 13.3.1.2. Key Management Personnel
    • 13.3.1.3. Products and Services
    • 13.3.1.4. Financials (As Reported)
    • 13.3.1.5. Key Market Focus and Geographical Presence
    • 13.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 13.3.2. Teva Pharmaceuticals Industries Ltd.
  • 13.3.3. Endo Pharmaceuticals Inc.
  • 13.3.4. Sanofi S.A.
  • 13.3.5. Daiichi Sankyo, Inc.
  • 13.3.6. Hikma Pharmaceuticals USA Inc.
  • 13.3.7. Purdue Pharma L.P.
  • 13.3.8. Mundipharma Pty Limited
  • 13.3.9. Protega Pharmaceuticals Inc.
  • 13.3.10. Mallinckrodt Pharmaceuticals plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer